Medtronic’s SynchroMed II Infusion Pain Treatment Proves Cost-Effective In Study
A new cost-effectiveness study shows cancer patients using targeted drug delivery with Medtronic’s SynchroMed II infusion system and conventional medical management incur lower overall health care costs than patients using conventional medical management alone.
You may also be interested in...
Medtronic Dodges Two Of Three Claims In Pain-Pump Suit
An Indiana federal judge axed two components of a patient’s lawsuit against Medtronic, while allowing a manufacturing defect complaint to move forward.
Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.
SISTERS Data Could Lift Medtronic's SynchroMed II From Recall Repercussions
The published results of the SISTERS trial demonstrate intrathecal baclofen (ITB) therapy with the recently redesigned SynchroMed II reduces spasticity-related pain and improves quality of life more than conventional medical management with oral antispastic medications in post-stroke patients suffering spasticity. The company hopes these results can boost interest in ITB and the SynchroMed II system while it works to resolve a 2015 consent decree with the FDA related to malfunctions with a previous version of the device.